

# Contents

Contents of all volumes	ix
Preface	xvii
Editors-in-Chief	xix
Contributors to Volume 8	xxi
Contributors of all Volumes	xxiii
<b>Personal Essays</b>	
8.01 Introduction	1
W T COMER, <i>TorreyPines Therapeutics, Inc., La Jolla, CA, USA</i>	
8.02 Reflections on Medicinal Chemistry Since the 1950s	7
H TIMMERMAN, <i>Vrije Universiteit, Amsterdam, The Netherlands</i>	
8.03 Medicinal Chemistry as a Scientific Discipline in Industry and Academia: Some Personal Reflections	17
C R GANELLIN, <i>University College London, London, UK</i>	
8.04 Some Aspects of Medicinal Chemistry at the Schering-Plough Research Institute	29
A K GANGULY, <i>Stevens Institute of Technology, Hoboken, NJ, USA</i>	
<b>Case Histories</b>	
8.05 Viread	53
R OLIYAI and M FARDIS, <i>Gilead Sciences Inc., Foster City, CA, USA</i>	
8.06 Hepsera	59
R OLIYAI and M FARDIS, <i>Gilead Sciences Inc., Foster City, CA, USA</i>	
8.07 Ezetimibe	65
J W CLADER, <i>Schering-Plough Research Institute, Kenilworth, NJ, USA</i>	
8.08 Tamoxifen	83
V C JORDAN, <i>Fox Chase Cancer Center, Philadelphia, PA, USA</i>	
8.09 Raloxifene	103
J LEWIS-WAMBI and V C JORDAN, <i>Fox Chase Cancer Center, Philadelphia, PA, USA</i>	

8.10	Duloxetine K B THOR, <i>Dynogen Pharmaceuticals, Inc., Research Triangle Park, Durham, NC, USA</i> and I YALÇIN, <i>Eli Lilly and Co., Indianapolis, IN, USA</i>	123
8.11	Carvedilol R R RUFFOLO and G Z FEUERSTEIN, <i>Wyeth Research Laboratories, Collegeville, PA, USA</i>	137
8.12	Modafinil, A Unique Wake-Promoting Drug: A Serendipitous Discovery in Search of a Mechanism of Action F RAMBERT, J F HERMANT, and D SCHWEIZER, <i>Cephalon France, Maisons-Alfort, France</i>	149
8.13	Zyvox S J BRICKNER, <i>Pfizer Inc., Groton, CT, USA</i>	157
8.14	Copaxone D TEITELBAUM, R ARNON, and M SELA, <i>Weizmann Institute of Science, Rehovot, Israel</i>	173
8.15	Ritonavir and Lopinavir/Ritonavir D J KEMPF, <i>Abbott, Abbott Park, IL, USA</i>	187
8.16	Fosamax A A RESZKA, <i>Merck Research Laboratories, West Point, PA, USA</i> and G A RODAN*, <i>University of Pennsylvania School of Medicine, Philadelphia, PA, USA</i>	199
8.17	Omeprazole P LINDBERG, <i>AstraZeneca R&amp;D, Mölndal, Sweden</i>	213
8.18	Calcium Channel $\alpha_2$ - $\delta$ Ligands: Gabapentin and Pregabalin A J THORPE and C P TAYLOR, <i>Pfizer Global Research and Development, Ann Arbor, MI, USA</i>	227
	Cumulative Subject Index	247

# Contents of all Volumes

## Volume 1 Global Perspective

### Historical Perspective and Outlook

- 1.01 Reflections of a Medicinal Chemist: Formative Years through Thirty-Seven Years Service in the Pharmaceutical Industry
- 1.02 Drug Discovery: Historical Perspective, Current Status, and Outlook
- 1.03 Major Drug Introductions

### The Impact of New Genomic Technologies

- 1.04 Epigenetics
- 1.05 Personalized Medicine
- 1.06 Gene Therapy

### Sources of New Drugs

- 1.07 Overview of Sources of New Drugs
- 1.08 Natural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals
- 1.09 Traditional Medicines
- 1.10 Biological Macromolecules
- 1.11 Nutraceuticals

### Animal Experimentation

- 1.12 Alternatives to Animal Testing

### The Role of Industry

- 1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery
- 1.14 The Role of the Pharmaceutical Industry
- 1.15 The Role of the Venture Capitalist
- 1.16 Industry–Academic Relationships

### Drug Discovery: Revolution, Decline?

- 1.17 Is the Biotechnology Revolution a Myth?
- 1.18 The Apparent Declining Efficiency of Drug Discovery

### Healthcare in the Social Context

- 1.19 How Much is Enough or Too Little: Assessing Healthcare Demand in Developed Countries
- 1.20 Health Demands in Developing Countries
- 1.21 Orphan Drugs and Generics

### Ethical Issues

- 1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment
- 1.23 Ethical Issues and Challenges Facing the Pharmaceutical Industry

### Funding and Regulation of Research

- 1.24 The Role of Government in Health Research
- 1.25 Postmarketing Surveillance

8.10	Duloxetine K B THOR, <i>Dynogen Pharmaceuticals, Inc., Research Triangle Park, Durham, NC, USA</i> and I YALÇIN, <i>Eli Lilly and Co., Indianapolis, IN, USA</i>	123
8.11	Carvedilol R R RUFFOLO and G Z FEUERSTEIN, <i>Wyeth Research Laboratories, Collegeville, PA, USA</i>	137
8.12	Modafinil, A Unique Wake-Promoting Drug: A Serendipitous Discovery in Search of a Mechanism of Action F RAMBERT, J F HERMANT, and D SCHWEIZER, <i>Cephalon France, Maisons-Alfort, France</i>	149
8.13	Zyvox S J BRICKNER, <i>Pfizer Inc., Groton, CT, USA</i>	157
8.14	Copaxone D TEITELBAUM, R ARNON, and M SELA, <i>Weizmann Institute of Science, Rehovot, Israel</i>	173
8.15	Ritonavir and Lopinavir/Ritonavir D J KEMPF, <i>Abbott, Abbott Park, IL, USA</i>	187
8.16	Fosamax A A RESZKA, <i>Merck Research Laboratories, West Point, PA, USA</i> and G A RODAN*, <i>University of Pennsylvania School of Medicine, Philadelphia, PA, USA</i>	199
8.17	Omeprazole P LINDBERG, <i>AstraZeneca R&amp;D, Mölndal, Sweden</i>	213
8.18	Calcium Channel $\alpha_2$ - $\delta$ Ligands: Gabapentin and Pregabalin A J THORPE and C P TAYLOR, <i>Pfizer Global Research and Development, Ann Arbor, MI, USA</i>	227
	Cumulative Subject Index	247

---

\*Deceased.

# Contents of all Volumes

## **Volume 1 Global Perspective**

### **Historical Perspective and Outlook**

- 1.01 Reflections of a Medicinal Chemist: Formative Years through Thirty-Seven Years Service in the Pharmaceutical Industry
- 1.02 Drug Discovery: Historical Perspective, Current Status, and Outlook
- 1.03 Major Drug Introductions

### **The Impact of New Genomic Technologies**

- 1.04 Epigenetics
- 1.05 Personalized Medicine
- 1.06 Gene Therapy

### **Sources of New Drugs**

- 1.07 Overview of Sources of New Drugs
- 1.08 Natural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals
- 1.09 Traditional Medicines
- 1.10 Biological Macromolecules
- 1.11 Nutraceuticals

### **Animal Experimentation**

- 1.12 Alternatives to Animal Testing

### **The Role of Industry**

- 1.13 The Role of Small- or Medium-Sized Enterprises in Drug Discovery
- 1.14 The Role of the Pharmaceutical Industry
- 1.15 The Role of the Venture Capitalist
- 1.16 Industry–Academic Relationships

### **Drug Discovery: Revolution, Decline?**

- 1.17 Is the Biotechnology Revolution a Myth?
- 1.18 The Apparent Declining Efficiency of Drug Discovery

### **Healthcare in the Social Context**

- 1.19 How Much is Enough or Too Little: Assessing Healthcare Demand in Developed Countries
- 1.20 Health Demands in Developing Countries
- 1.21 Orphan Drugs and Generics

### **Ethical Issues**

- 1.22 Bioethical Issues in Medicinal Chemistry and Drug Treatment
- 1.23 Ethical Issues and Challenges Facing the Pharmaceutical Industry

### **Funding and Regulation of Research**

- 1.24 The Role of Government in Health Research
- 1.25 Postmarketing Surveillance

## **Intellectual Property**

- 1.26 Intellectual Property Rights and Patents
- Subject Index

## **Volume 2 Strategy and Drug Research**

### **Introduction**

- 2.01 The Intersection of Strategy and Drug Research
- 2.02 An Academic Perspective
- 2.03 An Industry Perspective

### **Organizational Aspects and Strategies for Drug Discovery and Development**

- 2.04 Project Management
- 2.05 The Role of the Chemical Development, Quality, and Regulatory Affairs Teams in Turning a Potent Agent into a Registered Product
- 2.06 Drug Development
- 2.07 In-House or Out-Source
- 2.08 Pharma versus Biotech: Contracts, Collaborations, and Licensing
- 2.09 Managing Scientists, Leadership Strategies in Science
- 2.10 Innovation (Fighting against the Current)
- 2.11 Enabling Technologies in Drug Discovery: The Technical and Cultural Integration of the New with the Old
- 2.12 How and Why to Apply the Latest Technology
- 2.13 How and When to Apply Absorption, Distribution, Metabolism, Excretion, and Toxicity
- 2.14 Peptide and Protein Drugs: Issues and Solutions
- 2.15 Peptidomimetic and Nonpeptide Drug Discovery: Receptor, Protease, and Signal Transduction Therapeutic Targets
- 2.16 Bioisosterism
- 2.17 Chiral Drug Discovery and Development – From Concept Stage to Market Launch
- 2.18 Promiscuous Ligands

### **Targets**

- 2.19 Diversity versus Focus in Choosing Targets and Therapeutic Areas
- 2.20 G Protein-Coupled Receptors
- 2.21 Ion Channels – Voltage Gated
- 2.22 Ion Channels – Ligand Gated
- 2.23 Phosphodiesterases
- 2.24 Protein Kinases and Protein Phosphatases in Signal Transduction Pathways
- 2.25 Nuclear Hormone Receptors
- 2.26 Nucleic Acids (Deoxyribonucleic Acid and Ribonucleic Acid)
- 2.27 Redox Enzymes

List of Abbreviations

List of Symbols

Subject Index

## **Volume 3 Drug Discovery Technologies**

### **Target Search**

- 3.01 Genomics
- 3.02 Proteomics
- 3.03 Pharmacogenomics
- 3.04 Biomarkers
- 3.05 Microarrays
- 3.06 Recombinant Deoxyribonucleic Acid and Protein Expression
- 3.07 Chemical Biology

**Target Validation**

- 3.08 Genetically Engineered Animals
- 3.09 Small Interfering Ribonucleic Acids
- 3.10 Signaling Chains
- 3.11 Orthogonal Ligand–Receptor Pairs

**Informatics and Databases**

- 3.12 Chemoinformatics
- 3.13 Chemical Information Systems and Databases
- 3.14 Bioactivity Databases
- 3.15 Bioinformatics
- 3.16 Gene and Protein Sequence Databases
- 3.17 The Research Collaboratory for Structural Bioinformatics Protein Data Bank
- 3.18 The Cambridge Crystallographic Database

**Structural Biology**

- 3.19 Protein Production for Three-Dimensional Structural Analysis
- 3.20 Protein Crystallization
- 3.21 Protein Crystallography
- 3.22 Bio-Nuclear Magnetic Resonance
- 3.23 Protein Three-Dimensional Structure Validation
- 3.24 Problems of Protein Three-Dimensional Structures
- 3.25 Structural Genomics

**Screening**

- 3.26 Compound Storage and Management
- 3.27 Optical Assays in Drug Discovery
- 3.28 Fluorescence Screening Assays
- 3.29 Cell-Based Screening Assays
- 3.30 Small Animal Test Systems for Screening
- 3.31 Imaging
- 3.32 High-Throughput and High-Content Screening

**Chemical Technologies**

- 3.33 Combinatorial Chemistry
- 3.34 Solution Phase Parallel Chemistry
- 3.35 Polymer-Supported Reagents and Scavengers in Synthesis
- 3.36 Microwave-Assisted Chemistry
- 3.37 High-Throughput Purification

**Lead Search and Optimization**

- 3.38 Protein Crystallography in Drug Discovery
- 3.39 Nuclear Magnetic Resonance in Drug Discovery
- 3.40 Chemogenomics
- 3.41 Fragment-Based Approaches
- 3.42 Dynamic Ligand Assembly

Subject Index

**Volume 4 Computer-Assisted Drug Design****Introduction to Computer-Assisted Drug Design**

- 4.01 Introduction to the Volume and Overview of Computer-Assisted Drug Design in the Drug Discovery Process
- 4.02 Introduction to Computer-Assisted Drug Design – Overview and Perspective for the Future
- 4.03 Quantitative Structure–Activity Relationship – A Historical Perspective and the Future
- 4.04 Structure-Based Drug Design – A Historical Perspective and the Future

**Core Concepts and Methods – Ligand-Based**

- 4.05 Ligand-Based Approaches: Core Molecular Modeling
- 4.06 Pharmacophore Modeling: 1 – Methods
- 4.07 Predictive Quantitative Structure–Activity Relationship Modeling
- 4.08 Compound Selection Using Measures of Similarity and Dissimilarity

**Core Concepts and Methods – Target Structure-Based**

- 4.09 Structural, Energetic, and Dynamic Aspects of Ligand–Receptor Interactions
- 4.10 Comparative Modeling of Drug Target Proteins
- 4.11 Characterization of Protein-Binding Sites and Ligands Using Molecular Interaction Fields
- 4.12 Docking and Scoring
- 4.13 De Novo Design

**Core Methods and Applications – Ligand and Structure-Based**

- 4.14 Library Design: Ligand and Structure-Based Principles for Parallel and Combinatorial Libraries
- 4.15 Library Design: Reactant and Product-Based Approaches
- 4.16 Quantum Mechanical Calculations in Medicinal Chemistry: Relevant Method or a Quantum Leap Too Far?

**Applications to Drug Discovery – Lead Discovery**

- 4.17 Chemogenomics in Drug Discovery – The Druggable Genome and Target Class Properties
- 4.18 Lead Discovery and the Concepts of Complexity and Lead-Likeness in the Evolution of Drug Candidates
- 4.19 Virtual Screening
- 4.20 Screening Library Selection and High-Throughput Screening Analysis/Triage

**Applications to Drug Discovery – Ligand-Based Lead Optimization**

- 4.21 Pharmacophore Modeling: 2 – Applications
- 4.22 Topological Quantitative Structure–Activity Relationship Applications: Structure Information Representation in Drug Discovery
- 4.23 Three-Dimensional Quantitative Structure–Activity Relationship: The State of the Art

**Applications to Drug Discovery – Target Structure-Based**

- 4.24 Structure-Based Drug Design – The Use of Protein Structure in Drug Discovery
- 4.25 Applications of Molecular Dynamics Simulations in Drug Design
- 4.26 Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling
- 4.27 Ion Channels: Insights for Drug Design from Structure and Modeling
- 4.28 Nuclear Hormone Receptors: Insights for Drug Design from Structure and Modeling
- 4.29 Enzymes: Insights for Drug Design from Structure

**New Directions**

- 4.30 Multiobjective/Multicriteria Optimization and Decision Support in Drug Discovery
- 4.31 New Applications for Structure-Based Drug Design
- 4.32 Biological Fingerprints

Subject Index

**Volume 5 ADME-Tox Approaches**

**Introduction**

- 5.01 The Why and How of Absorption, Distribution, Metabolism, Excretion, and Toxicity Research

**Biological and In Vivo Aspects of Absorption, Distribution, Metabolism, Excretion, and Toxicity**

- 5.02 Clinical Pharmacokinetic Criteria for Drug Research
- 5.03 In Vivo Absorption, Distribution, Metabolism, and Excretion Studies in Discovery and Development
- 5.04 The Biology and Function of Transporters
- 5.05 Principles of Drug Metabolism 1: Redox Reactions



- 5.06 Principles of Drug Metabolism 2: Hydrolysis and Conjugation Reactions
- 5.07 Principles of Drug Metabolism 3: Enzymes and Tissues
- 5.08 Mechanisms of Toxicification and Detoxification which Challenge Drug Candidates and Drugs
- 5.09 Immunotoxicology
- Biological In Vitro Tools in Absorption, Distribution, Metabolism, Excretion, and Toxicity**
- 5.10 In Vitro Studies of Drug Metabolism
- 5.11 Passive Permeability and Active Transport Models for the Prediction of Oral Absorption
- 5.12 Biological In Vitro Models for Absorption by Nonoral Routes
- 5.13 In Vitro Models for Examining and Predicting Brain Uptake of Drugs
- 5.14 In Vitro Models for Plasma Binding and Tissue Storage
- 5.15 Progress in Bioanalytics and Automation Robotics for Absorption, Distribution, Metabolism, and Excretion Screening
- Physicochemical tools in Absorption, Distribution, Metabolism, Excretion, and Toxicity**
- 5.16 Ionization Constants and Ionization Profiles
- 5.17 Dissolution and Solubility
- 5.18 Lipophilicity, Polarity, and Hydrophobicity
- 5.19 Artificial Membrane Technologies to Assess Transfer and Permeation of Drugs in Drug Discovery
- 5.20 Chemical Stability
- 5.21 Solid-State Physicochemistry
- In Silico Tools in Absorption, Distribution, Metabolism, Excretion, and Toxicity**
- 5.22 Use of Molecular Descriptors for Absorption, Distribution, Metabolism, and Excretion Predictions
- 5.23 Electrotopological State Indices to Assess Molecular and Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties
- 5.24 Molecular Fields to Assess Recognition Forces and Property Spaces
- 5.25 In Silico Prediction of Ionization
- 5.26 In Silico Predictions of Solubility
- 5.27 Rule-Based Systems to Predict Lipophilicity
- 5.28 In Silico Models to Predict Oral Absorption
- 5.29 In Silico Prediction of Oral Bioavailability
- 5.30 In Silico Models to Predict Passage through the Skin and Other Barriers
- 5.31 In Silico Models to Predict Brain Uptake
- 5.32 In Silico Models for Interactions with Transporters
- 5.33 Comprehensive Expert Systems to Predict Drug Metabolism
- 5.34 Molecular Modeling and Quantitative Structure-Activity Relationship of Substrates and Inhibitors of Drug Metabolism Enzymes
- 5.35 Modeling and Simulation of Pharmacokinetic Aspects of Cytochrome P450-Based Metabolic Drug-Drug Interactions
- 5.36 In Silico Prediction of Plasma and Tissue Protein Binding
- 5.37 Physiologically-Based Models to Predict Human Pharmacokinetic Parameters
- 5.38 Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling for the Prediction of In Vivo Drug Concentration-Effect Relationships – Application in Drug Candidate Selection and Lead Optimization
- 5.39 Computational Models to Predict Toxicity
- 5.40 In Silico Models to Predict QT Prolongation
- 5.41 The Adaptive In Combo Strategy
- Enabling Absorption, Distribution, Metabolism, Excretion, and Toxicity Strategies and Technologies in Early Development**
- 5.42 The Biopharmaceutics Classification System
- 5.43 Metabonomics

5.44 Prodrug Objectives and Design

5.45 Drug-Polymer Conjugates

List of Abbreviations

List of Symbols

Subject Index

## **Volume 6 Therapeutic Areas I: Central Nervous System, Pain, Metabolic Syndrome, Urology, Gastrointestinal and Cardiovascular**

### **Central Nervous System**

6.01 Central Nervous System Drugs Overview

6.02 Schizophrenia

6.03 Affective Disorders: Depression and Bipolar Disorders

6.04 Anxiety

6.05 Attention Deficit Hyperactivity Disorder

6.06 Sleep

6.07 Addiction

6.08 Neurodegeneration

6.09 Neuromuscular/Autoimmune Disorders

6.10 Stroke/Traumatic Brain and Spinal Cord Injuries

6.11 Epilepsy

6.12 Ophthalmic Agents

### **Pain**

6.13 Pain Overview

6.14 Acute and Neuropathic Pain

6.15 Local and Adjunct Anesthesia

6.16 Migraine

### **Obesity/Metabolic Disorders/Syndrome X**

6.17 Obesity/Metabolic Syndrome Overview

6.18 Obesity/Disorders of Energy

6.19 Diabetes/Syndrome X

6.20 Atherosclerosis/Lipoprotein/Cholesterol Metabolism

6.21 Bone, Mineral, Connective Tissue Metabolism

6.22 Hormone Replacement

### **Urogenital**

6.23 Urogenital Diseases/Disorders, Sexual Dysfunction and Reproductive Medicine: Overview

6.24 Incontinence (Benign Prostatic Hyperplasia/Prostate Dysfunction)

6.25 Renal Dysfunction in Hypertension and Obesity

### **Gastrointestinal**

6.26 Gastrointestinal Overview

6.27 Gastric and Mucosal Ulceration

6.28 Inflammatory Bowel Disease

6.29 Irritable Bowel Syndrome

6.30 Emesis/Prokinetic Agents

### **Cardiovascular**

6.31 Cardiovascular Overview

6.32 Hypertension

6.33 Antiarrhythmics

6.34 Thrombolytics

Subject Index

**Volume 7 Therapeutic Areas II: Cancer, Infectious Diseases, Inflammation & Immunology and Dermatology****Anti Cancer**

- 7.01 Cancer Biology
- 7.02 Principles of Chemotherapy and Pharmacology
- 7.03 Antimetabolites
- 7.04 Microtubule Targeting Agents
- 7.05 Deoxyribonucleic Acid Topoisomerase Inhibitors
- 7.06 Alkylating and Platinum Antitumor Compounds
- 7.07 Endocrine Modulating Agents
- 7.08 Kinase Inhibitors for Cancer
- 7.09 Recent Development in Novel Anticancer Therapies

**Anti Viral**

- 7.10 Viruses and Viral Diseases
- 7.11 Deoxyribonucleic Acid Viruses: Antivirals for Herpesviruses and Hepatitis B Virus
- 7.12 Ribonucleic Acid Viruses: Antivirals for Human Immunodeficiency Virus
- 7.13 Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus

**Anti Fungal**

- 7.14 Fungi and Fungal Disease
- 7.15 Major Antifungal Drugs

**Anti Bacterials**

- 7.16 Bacteriology, Major Pathogens, and Diseases
- 7.17  $\beta$ -Lactam Antibiotics
- 7.18 Macrolide Antibiotics
- 7.19 Quinolone Antibacterial Agents
- 7.20 The Antibiotic and Nonantibiotic Tetracyclines
- 7.21 Aminoglycosides Antibiotics
- 7.22 Anti-Gram Positive Agents of Natural Product Origins
- 7.23 Oxazolidinone Antibiotics
- 7.24 Antimycobacterium Agents
- 7.25 Impact of Genomics-Emerging Targets for Antibacterial Therapy

**Drugs for Parasitic Infections**

- 7.26 Overview of Parasitic Infections
- 7.27 Advances in the Discovery of New Antimalarials
- 7.28 Antiprotozoal Agents (African Trypanosomiasis, Chagas Disease, and Leishmaniasis)

**I and I Diseases**

- 7.29 Recent Advances in Inflammatory and Immunological Diseases: Focus on Arthritis Therapy
- 7.30 Asthma and Chronic Obstructive Pulmonary Disease
- 7.31 Treatment of Transplantation Rejection and Multiple Sclerosis

**Dermatology**

- 7.32 Overview of Dermatological Diseases
- 7.33 Advances in the Discovery of Acne and Rosacea Treatments
- 7.34 New Treatments for Psoriasis and Atopic Dermatitis

Subject Index

**Volume 8 Case Histories and Cumulative Subject Index****Personal Essays**

- 8.01 Introduction
- 8.02 Reflections on Medicinal Chemistry Since the 1950s

- 8.03 Medicinal Chemistry as a Scientific Discipline in Industry and Academia: Some Personal Reflections
- 8.04 Some Aspects of Medicinal Chemistry at the Schering-Plough Research Institute
- Case Histories**
- 8.05 Viread
- 8.06 Hepsera
- 8.07 Ezetimibe
- 8.08 Tamoxifen
- 8.09 Raloxifene
- 8.10 Duloxetine
- 8.11 Carvedilol
- 8.12 Modafinil, A Unique Wake-Promoting Drug: A Serendipitous Discovery in Search of a Mechanism of Action
- 8.13 Zyvox
- 8.14 Copaxone
- 8.15 Ritonavir and Lopinavir/Ritonavir
- 8.16 Fosamax
- 8.17 Omeprazole
- 8.18 Calcium Channel  $\alpha_2$ - $\delta$  Ligands: Gabapentin and Pregabalin
- Cumulative Subject Index